The widespread belief that radiations from X-rays and CT scans can cause cancer has flaws and is based on an unproven theoretical model, suggests a study.
Researchers have found that depriving cancer cells of an essential nutrient could offer a promising new approach for the treatment of an aggressive form of kidney cancer.
Due to dietary factors, humans are taller now but taller people are more prone to the risk of cancer, warns a recent study.The taller people, though have lower risk for heart disease and Type-2 diabetes, said the study carried out by researchers in Germany.
Girls who eat more high-fibre foods during adolescence - especially lots of fruits and vegetables may have significantly lower breast cancer risk than those who eat less dietary fibre when young, new research has found.
Sun Pharma launched therapeutic equivalent to Gleevec® in the US market. Sun Pharma’s subsidiary received final approval for Imatinib Mesylate from FDA in December 2015.
U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
NextSource Biotechnology, LLC announced that Gleostine® (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration (FDA) and is now commercially available in the United States.
Genmab announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for the use of Arzerra® (ofatumumab) for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL). The application was submitted by Novartis under the ofatumumab collaboration between the two companies.
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
Maharshi Dayanand University, ab initio established as Rohtak University, Rohtak, came into existence by an Act No. 25 of 1975 of the Haryana Legislative Assembly in 1976 with the objective to promote inter-disciplinary higher education and research in the fields of environmental, ecological and life sciences. It was rechristened as Maharshi Dayanand University in 1977 after the name of a great visionary and social reformer, Maharshi Dayanand. It had a unitary and residential character in its nascent stage, but became an affiliating University in November 1978. The University secured the recognition of University Grants Commission – the higher education regulatory body of India - for central Govt. grants in Feb. 1983.
